Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Ther Methods Clin Dev ; 32(2): 101230, 2024 Jun 13.
Artículo en Inglés | MEDLINE | ID: mdl-38558570

RESUMEN

Recombinant adeno-associated virus (rAAV)-based gene therapy is entering clinical and commercial stages at an unprecedented pace. Triple transfection of HEK293 cells is currently the most widely used platform for rAAV manufacturing. Here, we develop low-cis triple transfection that decreases transgene plasmid use by 10- to 100-fold and overcomes several major limitations associated with standard triple transfection. This new method improves packaging of yield-inhibiting transgenes by up to 10-fold, and generates rAAV batches with reduced plasmid backbone contamination that otherwise cannot be eliminated in downstream processing. When tested in mice and compared with rAAV produced by standard triple transfection, low-cis rAAV shows comparable or superior potency and results in diminished plasmid backbone DNA and RNA persistence in tissue. Mechanistically, low-cis triple transfection relies on the extensive replication of transgene cassette (i.e., inverted terminal repeat-flanked vector DNA) in HEK293 cells during production phase. This cost-effective method can be easily implemented and is widely applicable to producing rAAV of high quantity, purity, and potency.

2.
EMBO Mol Med ; 16(4): 945-965, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38413838

RESUMEN

Physiological regulation of transgene expression is a major challenge in gene therapy. Onasemnogene abeparvovec (Zolgensma®) is an approved adeno-associated virus (AAV) vector gene therapy for infants with spinal muscular atrophy (SMA), however, adverse events have been observed in both animals and patients following treatment. The construct contains a native human survival motor neuron 1 (hSMN1) transgene driven by a strong, cytomegalovirus enhancer/chicken ß-actin (CMVen/CB) promoter providing high, ubiquitous tissue expression of SMN. We developed a second-generation AAV9 gene therapy expressing a codon-optimized hSMN1 transgene driven by a promoter derived from the native hSMN1 gene. This vector restored SMN expression close to physiological levels in the central nervous system and major systemic organs of a severe SMA mouse model. In a head-to-head comparison between the second-generation vector and a benchmark vector, identical in design to onasemnogene abeparvovec, the 2nd-generation vector showed better safety and improved efficacy in SMA mouse model.


Asunto(s)
Atrofia Muscular Espinal , Lactante , Humanos , Ratones , Animales , Atrofia Muscular Espinal/genética , Atrofia Muscular Espinal/terapia , Neuronas Motoras/metabolismo , Terapia Genética , Transgenes , Regiones Promotoras Genéticas , Modelos Animales de Enfermedad
3.
Nano Lett ; 23(11): 5194-5200, 2023 Jun 14.
Artículo en Inglés | MEDLINE | ID: mdl-37220138

RESUMEN

Solid polymer electrolytes (SPEs) are attractive for next-generation lithium metal batteries but still suffer from low ionic conductivity. Nanostructured materials offer design concepts for SPEs with better performance. Using molecular dynamics simulation, we examine SPEs under nanoscale confinement, which has been demonstrated to accelerate the transport of neutral molecules such as water. Our results show that while ion diffusion indeed accelerates by more than 2 orders of magnitude as the channel diameter decreases from 15 to 2 nm, the ionic conductivity does not increase significantly in parallel. Instead, the ionic conductivity shows a nonmonotonic variation, with an optimal value above, but on the same order as, its bulk counterparts. This trend is due to enhanced ion association with decreasing channel size, which reduces the number of effective charge carriers. This effect competes with accelerated ion diffusion, leading to the nonmonotonicity in ion conductivity.

4.
Natl Sci Rev ; 9(12): nwac148, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36713590

RESUMEN

While endogenous lipids are known to exhibit rhythmic oscillations, less is known about how specific lipids modulate circadian behavior. Through a series of loss-of-function and gain-of-function experiments on ceramide phosphoethanolamine (CPE) synthase of Drosophila, we demonstrated that pan-glial-specific deficiency in membrane CPE, the structural analog of mammalian sphingomyelin (SM), leads to arrhythmic locomotor behavior and shortens lifespan, while the reverse is true for increasing CPE. Comparative proteomics uncovered dysregulated synaptic glutamate utilization and transport in CPE-deficient flies. An extensive genetic screen was conducted to verify the role of differentially expressed proteins in circadian regulation. Arrhythmic locomotion under cpes1 mutant background was rescued only by restoring endogenous CPE or SM through expressing their respective synthases. Our results underscore the essential role of CPE in maintaining synaptic glutamate homeostasis and modulating circadian behavior in Drosophila. The findings suggest that region-specific elevations of functional membrane lipids can benefit circadian regulation.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...